Differences of EDR Chemoresistance Assay and Prognosis between Recurrent Micropapillary Serous Ovarian Carcinoma and Serous Ovarian Carcinoma / 대한산부인과학회지
Korean Journal of Obstetrics and Gynecology
;
: 1655-1659, 2006.
Article
in Korean
| WPRIM
| ID: wpr-107647
ABSTRACT
OBJECTIVE:
The purpose of this study was to identify chemoresistance and prognosis differences between recurrent micropapillary serous ovarian carcinoma (MPSC) and serous ovarian carcinoma.METHODS:
The Extreme drug resistance (EDR) assay was performed in 13 recurrent micropapillary serous ovarian carcinoma and 56 recurrent serous ovarian carcinoma.RESULTS:
Mean age of MPSC and Serous ovarian cancer were 41.1 and 58.0 respectively (p<0.05). Etoposide and Doxil were the two least resistance chemotherapeutic agents to recurrent MPSC but the most resistance agents to recurrent serous ovarian cancer. Taxol and cisplatin were the two most resistance agents to MPSC. The mean follow up was 42 months (range 1-173) The five-year overall survival rate of MPSC and serous ovarian carcinoma were 71.6% and 33.9% respectively. The mean survival were 136 months in MPSC compared with 72 months in serous ovarian carcinoma (p<0.035).CONCLUSION:
In this retrospective analysis, MPSC showed very different in EDR results and favorable prognosis compare to serous ovarian carcinoma.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Ovarian Neoplasms
/
Prognosis
/
Drug Resistance
/
Survival Rate
/
Retrospective Studies
/
Follow-Up Studies
/
Cisplatin
/
Paclitaxel
/
Etoposide
Type of study:
Observational study
/
Prognostic study
Language:
Korean
Journal:
Korean Journal of Obstetrics and Gynecology
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS